Methysergide-induced valvular heart disease: a report of 2 cases.

Abstract

Methysergide is a serotonin antagonist and is used as a long-term prophylactic treatment for migraine. Although many patients experience adequate control of migraine episodes, methysergide has been reported to cause retroperitoneal and pleuropulmonary fibrosis. Cardiovascular side effects mainly in the form of valvular fibrosis have been less recognized. We report 2 cases of methysergide-related mitral valve fibrosis.

• Authors: Ali M Alizzi, Ayman H Al-Masri, Mark M Murton, Anand S Dixit, Jonathan M Hemli, Michael Challis, Tuck Yong, Michael R Nicholson
• Journal: The heart surgery forum (Heart Surg Forum) Vol. 9 Issue 5 Pg. E792-3 ( 2006) ISSN: 1522-6662 [Electronic] United States
• PMID: 17099974 (Publication Type: Case Reports, Journal Article)

Chemical References

• Serotonin Antagonists
• Methysergide

Topics

• Female
• Fibrosis
• Heart Valve Diseases (chemically induced, surgery)
• Heart Valve Prosthesis Implantation
• Humans
• Methysergide (adverse effects)
• Middle Aged
• Mitral Valve (pathology)
• Serotonin Antagonists (adverse effects)